Improving microcirculation for weight reduction in obesity
4 things you should know about erectile dysfunction
D’OXYVA® on cellulite and fat reduction
Results of several human studies with D'OXYVA® (including randomized, placebo-controlled, double-blind) promise treating microcirculation defects in cardiovascular disease

Over two dozen studies demonstrated sterling results at clinics and at home with zero major adverse event reports. D’OXYVA® (deoxyhemoglobin vasodilator) has recorded significant results, delivering major clinical outcomes for well over 90% of users.

Average results rounded for display, based on number of enrolled subjects in each study with D’OXYVA® and user feedback.

Read D’OXYVA® Clinical Evidence

Ask your doctor before taking D’OXYVA®.

Read D’OXYVA® Regulatory Statements

We will refund your entire D’OXYVA® purchase price if you do not achieve any measurable improvements (proof of purchase required, improvements of blood flow (perfusion index) measured from absolute baseline without taking D’OXYVA®).

Read Circularity’s Return Policy

✔ vasodilation and vasoconstriction in the vessels

✔catalyzing vessel structure growth (angiogenesis)

✔ auto-regulation of local blood supply in tissues and organs

✔ neuro-receptor signaling in the brain

✔ balancing blood pH, blood sugar, and other critical functions

Recommended By World-Class Medical Experts
9 Years Of Amazing User Feedback & Over 2 Dozen Successful Human Studies
Underpinned By Nobel-Winning Science

Circularity Healthcare has been assembling a world-class scientific advisory board (partial list) that includes domestic and international medical thought-leaders in the field of diabetic relief, amputation prevention, micro-vascular physiology, neurology, endocrinology, vascular surgery, cardiovascular physiology, exercise science and others.

D’OXYVA® has demonstrated an exceptional efficacy and safety profile in quality human pivotal clinical studies including placebo-controlled double-blind, randomized trials and has been investigated at prestigious institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others. Currently, its diabetic foot ulcer closure human pivotal trials are expanding to over a dozen top U.S. universities conducted by influential medical experts who are regularly called upon to testify in front of the U.S. Food and Drug Administration (FDA).

Improved oxygen-rich microcirculatory tissue perfusion is widely reported in published research to improve physiological processes that lead to significant health benefits and outcomes. These include, but are not limited to chronic, burn, trauma wound and tissue improvement and repair, boosting athletic performance, stamina, sleep quality, fading the appearance of spider and varicose veins, while aiding in skin health, and much more.

D’OXYVA has recorded instant, outsized, and sustained improvements of the autonomic nervous system (ANS) in the brain, enhanced tissue perfusion and blood circulation in macro-, and microcirculation, chronic wound closure and balanced blood pressure in controlled human studies.

The D’OXYVA mechanical applicator is a handheld, non-invasive skin infusion technology. Therefore, it is a non-significant risk (NSR) device, according to FDA guidelines.

Please contact us if you would like participate as a subject or health professional in Circularity’s clinical study program called the Center of Excellence (COE) program.

Prof Judy Delp D'OXYVA how to increase blood flow in foot
Source: Prof. Judy Delp, PhD - Florida State University


✔ D’OXYVA® improved microcirculation (Skin Perfusion Pressure) in a statistically significant manner in 100% of subjects by about 15-100% from absolute baseline (median over 40%)

✔ Improvement in blood flow peaked uniformly within 1 hour after a single 5-minute delivery on their thumb, and subsequently lasted for over 4 hours

✔ 100% of enrolled subjects responded positively without adverse event reports after being monitored for a year after the study

          BUY D’OXYVA

Fill out the form and receive more detailed information about D’OXYVA’s outstanding results!


Expert Reviews



Expert Interviews

Dr. Geoffrey Watson
Dr. Geoffrey Watson
Watson Wellness Center in Oakland, CA
"D’OXYVA has shown significant promise for severe cases of diabetic foot ulcers. Its therapeutic effects have circulatory and neurological benefits as well."
Dr. Michael McGlamry
Dr. Michael McGlamry
Forsyth Foot and Ankle Associates, Cumming, GA
"D’OXYVA demonstrated hastened wound improvement and eventual wound closure in an average of 5 weeks**."
Dr. Felix Sigal
Dr. Felix Sigal
Foot and Ankle Clinic, Los Angeles Podiatrist
"D'OXYVA has the potential to prevent symmetrical peripheral gangrene, a limb-threatening complication of COVID-19."


Blog Posts

Reduce unwanted doctor visits, recommended and ranked top by experts!